Introduction {#S5}
============

Prostate cancer is a prevalent, costly disease for which guideline-recommended treatment options are equivocal for most men ([@R1]--[@R3]). Although primary gonadotropin-releasing hormone (GnRH) agonists are recommended for men with metastatic disease and adjuvant to radiation for some men with localized disease, use of GnRH agonists alone in localized disease was recommended only for a small group of patients from 2000--2003, making most use in absence of radiation *overuse* ([@R4]--[@R7]).

Despite scant data supporting clinical effectiveness, GnRH agonist use in localized disease grew steadily from the 1990s, peaking in 2003 ([@R8]). Although clinical characteristics and patient preferences were thought to influence overuse, most variation in treatment has been attributed to the practice style of urologists, who prescribe over 90% of all GnRH agonists used in prostate cancer ([@R9]). In 2003, the Medicare Modernization Act (MMA) targeted wide variation in physician reimbursement of drugs covered under Medicare Part B (including GnRH agonists). The standardization, implemented incrementally in 2004 and 2005, decreased reimbursement for GnRH agonists 65% ([@R10]).

Whereas oncologists' response to MMA cuts was to increase the use of recommended chemotherapies ([@R11], [@R12]), urologists maintained GnRH agonist use in patients for whom it was recommended but decreased overuse in patients for whom it was non-recommended ([@R8]). By 2005, GnRH agonist overuse declined 34%; however, 25.7% of men for whom it was not recommended still received this treatment in 2005 ([@R13]). Understanding characteristics of urologists who persistently overuse GnRH agonists---despite reimbursement change---is essential to improving quality of care. Whether response within urology was uniform is unknown. Urologists are delaying retirement ([@R14]). Physicians who have practiced longer may be least receptive to reimbursement pressures to change practice ([@R11]) and contribute to persistent overuse. However, results of previous studies exploring time in practice and quality of care conflict ([@R15]). In addition, more urologists practice as solo practitioners than any other surgical specialty ([@R16]). Solo practice type is associated with poorer quality of care in primary care ([@R17]), but to our knowledge this has not been tested in specialty care.

We describe physician-level patterns of overuse and the effect of time in practice and solo practice type on persistent GnRH agonist overuse. We hypothesize urologists with greater time in practice and those in solo practice are less responsive to reimbursement change.

Materials and Methods {#S6}
=====================

We conducted a retrospective, longitudinal analysis using a national population-based sample of elderly prostate cancer patients. The study was approved by the Institutional Review Board of the University of North Carolina.

Data Sources {#S7}
------------

We linked Surveillance, Epidemiology and End Results (SEER)-Medicare data to the American Medical Association physician Masterfile. SEER includes 17 population-based cancer registries ([@R18]). Medicare administrative claims cover medical services for more than 97% of the U.S. population ≥65 years, approximately 81% of whom are covered under fee-for-service ([@R19], [@R20]). The Masterfile includes training and certification records supplemented by data from regulatory agencies and physician self-report for approximately 800,000 member and non-member U.S. physicians ([@R21]).

Cohort Definition {#S8}
-----------------

### Patients {#S9}

We identified men diagnosed with their first and only cancer as incident adenocarcinoma of the prostate between January 1, 2000 and December 31, 2007. We excluded patients whose comorbidities and/or initial treatment could not be ascertained with Medicare data: age \<66 years, lacking a complete year of claims; diagnosed at autopsy, death certificate, or at nursing/convalescent facility; not enrolled in fee-for-service (defined as continuous Part A and B coverage and not in an HMO for at least 12 months post diagnosis); died within 12 months of diagnosis; and/or diagnosed in Louisiana (due to disruptions in health services caused by Hurricane Katrina). The Tumor Node Metastasis staging system was used to restrict the cohort to patients for whom GnRH agonists are not National Comprehensive Cancer Network (NCCN) guideline-recommended across the study period: no evidence of nodal or metastatic involvement and no greater than unilateral, stage T2 tumors and World Health Organization grades 1--2. We mapped Extent of Disease-1988 3rd edition variables for patients diagnosed from 2000--2003 and Collaborative Staging variables for patients diagnosed 2004--2007 to American Joint Committee on Cancer staging categories used by NCCN ([@R4]). Because of changes in staging over the study period, the cohort excluded men diagnosed with 1) T1 or T2 cancers with Gleason scores 8--10; 2) T2b tumors before 2002 when the staging definition changed; 3) T2c tumors after 2002 when the category was added; or, 4) T3a tumors([@R8]). Guideline-recommended use of GnRH agonists in men receiving external beam radiation is dependent on D'Amico risk for recurrence ([@R7]). Prior to 2004, SEER did not collect prostate-specific antigen levels, one of three indicators used to determine D'Amico risk. Therefore, because we could not determine whether or not receipt of GnRH agonists constituted overuse, men receiving external beam radiation therapy were also excluded from the cohort.*Physicians*. Urologists prescribed 94.6% of GnRH agonists observed. The urologist responsible for the majority of prostate cancer-related initial treatment claims was considered the treating urologist.

Measures {#S10}
--------

### Dependent Variable {#S11}

*GnRH agonist overuse* was defined as having an initial treatment claim for a HealthCare Common Procedure Coding System code for a GnRH agonist administered within 1 year from date of diagnosis without another non-surveillance prostate treatment administered within the treatment window. Non-surveillance treatments included orchiectomy (not subject to reimbursement changes), radical prostatectomy, all forms of radiation therapy planned or delivered, chemotherapy, and cryotherapy ([Appendix Table 1](#SD2){ref-type="supplementary-material"}). Any primary use of GnRH agonists in localized disease was considered inappropriate use by the American Urological Association and NCCN clinical practice guidelines in effect during the study period and is thus considered *overuse* in our cohort ([@R4], [@R7], [@R22], [@R23]). The binary dependent variable compares men receiving primary GnRH agonists with men receiving prostate cancer treatments other than external beam radiation.

### Explanatory Variables {#S12}

*Time in practice* was calculated as the difference between SEER diagnosis date (averaged as the 15th day of month) and date of the urologists' medical degree. We dichotomized time in practice (\<20 versus ≥20 years). This specification best fit our data reflecting urology practice patterns, varying slightly from other studies ([@R24]). *Practice type* was taken from the AMA Masterfile in which physicians self-report their practice as solo or group. We also included a category for missing.

### Control Variables {#S13}

We controlled for changes due to MMA and other temporal factors by including indicator variables for diagnosis in pre-MMA (2000--2003); MMA implementation (2004--2005); and post-MMA (2006--2007) periods.

We controlled for: (1) *physician gender*; (2) *medical professionalization* defined as a binary indicator of board certification and degree of affiliation with an academic institution (none/some/missing);([@R25], [@R26]) and (3) *training location* (U.S./non-U.S.). Practice factors included *panel size*, (tertile of Medicare fee-for-service prostate cancer patients/year/urologist) ([@R27]); and tertile of *proportion of minority Medicare patients* ([@R28]).

At the patient level, we controlled for *grade* (WHO categories 1/2/missing), *stage* (T1/T2), *age, comorbidities* (NCI Comorbidity Index with uniform weights ([@R29], [@R30])) and marital status (married or living with partner/single, widowed, or divorced/missing). Missing categories were created because these data have been shown to be missing in a non-random manner ([@R31]). Thus, their exclusion may bias results. We also assessed *proclivity to seek care* (any primary care physician claim in the 12 months prior to diagnosis ([@R32])) and men's use of consultations in the prostate cancer treatment decision ([@R33]). A *primary care consultation* was \>1 visit to the same primary care physician occurring in both 1) the 12 months prior to diagnosis; and, 2) the window between diagnosis and treatment ([@R33]). *Specialist Care* included three binary variables indicating the presence of ≥1 prostate-related claim filed by a radiation oncologist, urologist, or medical oncologist between diagnosis and the earlier of first treatment or 12 months ([@R33]). Geographic indicators included: *SEER region*; *rurality* of the patient's community at diagnosis (\<2,500 residents/≥2,500 residents); and *community deprivation* measured by quartile of median income of the patients' residential zip code and quartile of proportion of adults without high-school education in the patients' residential zip code.

Analysis {#S14}
--------

Unadjusted analyses included t-tests and analysis of variance (continuous variables) and Pearson chi-squared tests (binary/categorical variables). Because prior studies demonstrate high intraclass correlation among prostate cancer providers ([@R9]), we used multilevel mixed effects logistic regression models ([@R34]) to calculate odds ratios (OR), 95% confidence intervals (CI) and differential effects. We calculated the fixed portion of marginal effects in each MMA period using mean and modal values of covariates. Interaction terms were constructed to test differential effects of time in practice by MMA period.

Model fit was tested in a 50% random sample. Likelihood ratio tests determined appropriateness of inclusion of model constructs and allowing both intercepts and slopes to vary randomly by urologist. We compared random slope and random intercept model fit with the Bayesian Information Criterion (BIC). Stata/SE 12.1 was used for all analyses ([@R35]).

### Sensitivity Analysis {#S15}

Some men may have been eligible for GnRH agonists. Because we could not exclude men based on prostate-specific antigen (PSA) levels (1 of 3 criteria for stratification) ([@R36]), analyses were repeated among men with \<5 years actuarial life expectancy at diagnosis: age \<88 for all years, except 2004 (age 89) and 2005 (age 87) ([@R37]--[@R43]).

Results {#S16}
=======

The final sample included 12,943 men diagnosed with T1 and T2 well- or moderately-differentiated prostate cancer from 2000 through 2007, and treated through 2008 by 2,138 urologists ([Figure 1](#F1){ref-type="fig"}).

GnRH Agonist Overuse {#S17}
--------------------

Among men treated 2000--2008, 18.5% received GnRH agonists without other therapy ([Table 1](#T1){ref-type="table"}). GnRH agonist overuse decreased from 21.0% before MMA implementation to 17.6% during the implementation phase, and to 13.6% following full policy deployment.

Physician Practice Patterns {#S18}
---------------------------

Although GnRH agonist overuse declined, unadjusted analysis showed three patterns of urologist response ([Figure 2](#F2){ref-type="fig"}). *Static users* (n=1,478) had low levels of use at entry into the cohort and either continued to use primary GnRH agonists infrequently following MMA or contributed data in only one period. This group treated the most patients (n=5,809). *Decreasing users* (n=394), had highest levels of GnRH agonist overuse in 2000 (averaged 23.1% over the period), but decreased sharply in 2004 and, by 2008, were similar to static users. *Increasing users* (n=276) sharply increased GnRH agonist overuse in 2004 and maintained even higher levels of overuse after MMA implementation. Their average overuse was 32.6% among the 2,817 patients they treated over the study period. Non-responders, those with low rates of use remaining stable over time, differed from responders in both physician characteristics and patient panels (data not shown). Patient panels of increasing users were significantly different from those of decreasing users ([Appendix Table 2](#SD2){ref-type="supplementary-material"}), although urologists whose overuse increased were not different than urologists whose overuse decreased ([Appendix Table 3](#SD2){ref-type="supplementary-material"}). Increasing users' patients were older, had more comorbid conditions, were more likely to be non-Hispanic black or "other" race, resided in communities with fewer resources, and were less likely to receive radiation oncology consultations.

Unadjusted Analysis {#S19}
-------------------

In unadjusted analysis, GnRH agonist overuse among urologists with greater time in practice declined less sharply compared to their less-practiced counterparts ([Figure 3](#F3){ref-type="fig"}). Overall, 19.4% of patients of urologists with ≥20 years in practice received primary GnRH agonist whereas 16.9% of patients of urologists practicing \<20 years received it. Compared to urologists in practice \<20 years, patients of longer-practicing urologists were: slightly older, spread disproportionately across SEER regions, and more likely to be non-Hispanic black, Hispanic, unmarried, or live in communities with fewer resources. Urologists in practice ≥20 years also differed on physician characteristics. Across the study period GnRH agonist overuse among patients seen by a urologist practicing alone was higher than that among patients seen in a group practice or whose practice type was missing (25.8%, 16.7% and 14.0%,respectively, p\<0.001; [Table 1](#T1){ref-type="table"}). Compared to patients seen in a group practice, patients of solo practitioners were: slightly older, spread disproportionately across SEER regions, more likely to be Hispanic or "Other" race/ethnicity, live in communities with fewer resources, and have well-differentiated tumors or missing grade information and have more comorbidities ([Table 2](#T2){ref-type="table"}).

Adjusted Analysis {#S20}
-----------------

A multilevel random intercepts model best fit training data; coefficients were similar in validation data. The interaction of time in practice and MMA period was not jointly significant and therefore not included in the model ([Table 3](#T3){ref-type="table"}). After adjusting for patient and urologist characteristics and secular changes, time in practice was not associated with GnRH agonist overuse or increasing overuse (OR 0.89, 95% CI 0.75, 1.05). Being seen by a solo practitioner substantially increased the odds of GnRH agonist overuse compared to being seen in group practice (OR 1.65, 95% CI 1.34, 2.02). Having a medical school affiliation was associated with lower odds of overuse (OR 0.65, 95% CI 0.55, 0.77), compared to those with no affiliation.

At the patient level, increased age, greater comorbidity, being in a racial/ethnic minority, high primary care utilization in the prior year, and receiving a radiation oncology consultation prior to treatment were associated with increased odds of GnRH agonist overuse ([Table 3](#T3){ref-type="table"}). Receiving a primary care consultation (OR 0.42; 95% CI 0.37--0.48) and being in the highest income category (OR 0.66; 95% CI 0.50--0.88) were associated with lower odds of GnRH agonist overuse.

In sensitivity analysis, removing 453 men guideline-ineligible for primary GnRH agonists by virtue of age and diagnosis year produced similar results. Differential effects based on covariates' mean and modal values confirmed OR interpretations ([Appendix Table 4](#SD2){ref-type="supplementary-material"}).

Discussion {#S21}
==========

Consistent with other studies, we found that GnRH agonist overuse declined precipitously over the 2000s, coincident with reimbursement policy changes ([@R8], [@R13]). Rates of overuse found in this study were between other published estimates and reflected a blending of two previously published sampling strategies and outcome definitions ([@R8], [@R13]). Further, overuse continued on a downward trajectory in the two years following MMA implementation. Nonetheless, GnRH agonist overuse remained, with 14% of men with T1 or T2 well- or moderately-differentiated tumors prescribed primary GnRH agonists in the post-MMA period.

Although GnRH agonist overuse significantly declined in the aggregate, we identified three distinct responses to the reimbursement change: static users, decreasing users, and increasing users. We were unable to distinguish increasing users from decreasing users based on physician characteristics measured. Increasing users' access to referral networks and urologist-level preferences for medical versus surgical intervention may explain these findings and deserve further study. Although we cannot distinguish whether urologists were responding to a changing patient population, these urologists were more likely to treat older patients and minority patients. No evidence suggests these patients benefit from GnRH agonists and they may have risk profiles making them more vulnerable to the harms of overuse. Future research should examine whether overuse in these populations, which remains over 30%, resulted from unmeasured frailty, incomplete disease severity reporting, patient preference, or physician bias. Moreover, future research should explore why urologists of these patients may be reluctant to encourage active surveillance ([@R44]).

Among all urologists, time in practice was not associated with GnRH agonist overuse, which is consistent with two earlier studies ([@R27], [@R45]), but not others ([@R15]). Reimbursement context may account for these mixed results. Studies finding an association of time in practice and poor quality of care were conducted in HMOs, HMO-penetrated states, and the Canadian health system, rather than in fee-for-service Medicare ([@R15], [@R46]). This suggests that more practiced physicians may succumb to clinical inertia or lapsed technical skill, but aligning financial incentives with quality of care may moderate this effect.

We found higher GnRH agonist overuse among solo practitioners than urologists in group practices (25.7% versus 17.1% of patients). Because more urologists (23%) practice as solo practitioners than any other surgical specialty ([@R16]), they are an important target for intervention. However, it will be important to understand why solo practitioners appear less responsive to MMA policy changes. Studies examining physician characteristics of GnRH agonist overuse have not considered practice type ([@R27], [@R45]), but solo practice has been identified as a barrier to innovation adoption ([@R47]). Whether the added financial vulnerability of urologists practicing on their own, isolation from timely and relevant knowledge, or lack of peer comparison discourages adoption of quality practice should be determined. Meaningful use provisions and efforts to reorganize practices into accountable care networks have placed pressure on smaller and solo practices to be subsumed into larger multispecialty and academic practices ([@R48]). These practice-level changes may result in new patterns of care; however, further study of environmental and/or culture change to promote quality is needed.

Urologists who overuse GnRH agonists also were more likely to lack affiliation with a medical school, which may make them hard to reach for intervention. Medical school-affiliated physicians may have resources (e.g., trainees, tumor boards) that encourage guideline-concordant practice; however, they may also lack motivation for financial gain ([@R49]). We cannot identify reasons for the association, but either could make it difficult to engage these urologists in traditional quality improvement efforts.

Our study has several limitations. First, generalizability may be limited because we: (1) excluded patients treated by non-physician providers; (2) restricted our study to urologists because they make most treatment decisions about GnRH agonist for patients with localized prostate cancer; and, (3) did not study men ≤65 years. Also limiting generalizability is that patients in SEER may not reflect the US. However the SEER population is comparable to the US along many demographic characteristics ([@R18]) and characteristics of urologists in our study mirror national trends ([@R50]). Second, administrative claims data are subject to errors in coding which can potentially lead to biased results ([@R51]). However, variables required to support payment of claims (e.g., treatment) have been shown to be highly reliable, especially those that are well remunerated such as GnRH agonists ([@R52]--[@R55]). Thus we would not expect the measurement of GnRH agonist overuse to be affected. Finally, we lacked PSA information necessary to exclude a small group of men with high-risk disease. However, misclassification should be small because only 14% of *all* prostate cancer patients (including those with advanced disease) are thought to have PSA levels \>20 ng/mL---the cut point for high-risk disease and many men with high-risk disease had more than one risk factor. Moreover, when conducting a sensitivity analysis that removed patients with ≥5 years life expectancy, the results did not change.

Conclusions {#S22}
===========

Approximately 30--40% of healthcare spending in the U.S. has been attributed to *overuse*, the provision of unnecessary care for which harms outweigh benefits ([@R56], [@R57]). Overuse results in patient harms, health disparities, and waste in a healthcare system already stretched to capacity ([@R57]). Despite being designated a significant quality problem and national priority ([@R58]), relatively little research focuses on the problem of overuse or strategies to address it ([@R56]). We identified important nuances in response to reimbursement changes designed to limit overuse, consequences of persistent overuse, and a group of urologists who may need additional support in reducing GnRH agonist overuse, which remains high among professionally isolated urologists, despite a significant decline during and after MMA implementation.
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###### 

Patient Characteristics by Physician Practice Type

                                                                     Solo            Group           Missing       
  ------------------------------------------------------------------ --------------- --------------- ------------- -----------
                                                                     **N=2,749**     **N=9,658**     **N=536**     
  **GnRH agonist overuse**                                           709 (25.8%)     1,616(16.7%)    75 (14.0%)    *\<0.001*
  **MMA Implementation Period**                                                                                    *\<0.001*
  Pre-MMA                                                            1,601 (58.2%)   5,202 (53.9%)   221 (41.2%)   
  MMA Implementation                                                 590 (21.5%)     2,261 (23.4%)   139 (25.9%)   
  Post-MMA                                                           558 (20.3%)     2,195 (22.7%)   176 (32.8%)   
  **T Stage**                                                                                                      *0.09*
  T1                                                                 2,156 (78.4%)   7,747 (80.2%)   435 (81.2%)   
  T2                                                                 593 (21.6%)     1,911 (19.8%)   101 (18.8%)   
  **Grade**                                                                                                        *\<0.001*
  Well-differentiated, 2--4                                          188 (6.8%)      441 (4.6%)      21 (3.9%)     
  Moderately-differentiated, 5--7[\*](#TFN5){ref-type="table-fn"}    2,496 (90.8%)   9,023 (93.4)%   506 (94.4%)   
  Missing                                                            65 (2.4%)       194 (2.0%)      9 (1.7%)      
  **Comorbidities**                                                                                                *\<0.001*
  0                                                                  1,754 (63.8%)   6,569 (68.0%)   385 (71.8%)   
  1                                                                  633 (23.0%)     2,041 (21.1%)   99 (18.5%)    
  2                                                                  197 (7.2%)      643 (6.7%)      30 (5.6%)     
  ≥3                                                                 165 (4.6%)      405 (4.2%)      22 (6.0%)     
  **Mean Age (SD)**                                                  74.9 (6.2)      73.9 (6.1)      73.7 (6.0%)   *\<0.001*
  **Race/ethnicity**                                                                                               *\<0.001*
  Non-Hispanic White                                                 1,993 (72.5%)   7,685 (79.6%)   398 (74.3%)   
  Non-Hispanic Black                                                 179 (6.5%)      632 (6.5%)      48 (9.0%)     
  Hispanic                                                           310 (11.3%)     618 (6.4%)      40 (7.5%)     
  Other                                                              187 (6.8%)      306 (3.2%)      34 (6.3%)     
  Missing                                                            80 (2.9%)       417 (4.3%)      16 (3.0%)     
  **Marital Status**                                                                                               *\<0.001*
  Not Married                                                        603 (19.0%)     1,833 (19.7%)   114 (21.9%)   
  Married                                                            1,791 (65.2%    6,689 (69.3%    374 (69.8%)   
  Missing                                                            355 (12.9%)     1,136 (11.8%)   48 (9.0%)     
  **Visits in Previous Year**                                                                                      *\<0.001*
  0--2 visits                                                        552 (20.1%)     1,798 (18.6%)   100 (18.7%)   
  3--5 visits                                                        1,090 (39.7%)   4,292 (44.4%    257 (47.9%)   
  ≥6 visits                                                          1,107 (40.3%    3,568 (36.9%)   179 (33.4%)   
  **Primary Care Consultation**                                      1,484 (54.0%)   5,462 (56.6%)   312 (58.2%)   *0.03*
  **Radiation Oncology Consultation**                                360 (13.1%)     1,510 (15.6%)   90 (16.8%)    *0.003*
  **Medical Oncology Consultation**                                  80 (2.9%)       367 (3.8%)      25 (4.7%)     *0.04*
  **Urology Consultation**                                           2,718 (98.9%)   9,559 (99.0%)   531 (99.1%)   *0.87*
  **Rural Residence**                                                55 (2.0%)       1484 (1.9%)     8 (1.5%)      *0.73*
  **SEER Region**                                                                                                  *\<0.001*
  Seattle                                                            141 (5.1%)      417 (4.3%)      13 (2.4%)     
  Connecticut                                                        139 (5.1%)      633 (6.6%)      10 (1.9%)     
  Detroit                                                            192 (7.0%)      686 (7.1%)      30 (5.6%)     
  Hawaii                                                             29 (1.1%)       83 (0.9%)       10 (1.9%)     
  Iowa                                                               58 (2.1%)       718 (7.4%       23 (4.3%)     
  New Mexico                                                         132(4.8%)       346 (3.6%)      13 (2.4%)     
  California                                                         1,356 (49.3%)   3,448 (35.7%)   272 (50.7%)   
  Utah                                                               57 (2.1%)       481 (5.0%)      18 (3.4%)     
  Georgia                                                            52 (1.9%)       267 (2.8%)      25 (4.7%)     
  Kentucky                                                           267 (9.7%)      964 (10.0%)     29 (5.4%)     
  New Jersey                                                         326 (11.9%)     1,615 (16.7%)   93 (17.4%)    
  **Median Income of Patients\' Communities**                                                        *\<0.001*     
  \<\$35,031                                                         700 (25.5%)     1,876 (19.4%)   106 (19.8%)   
  \$35,051--\$46,079                                                 674 (24.5%)     2,432 (25.2%)   108 (20.2%)   
  \$46,084--\$60,668                                                 618 (22.5%)     2,386 (24.7%)   139 (25.9%)   
  \$60,669--\$200,008                                                632 (23.0%)     2,556 (26.5%)   157 (29.3%)   
  Missing                                                            125 (4.6%)      408 (4.2%)      26 (4.9%)     
  **Proportion of Patient\'s Community w/o High-school Education**                   *\<0.001*                     
  0%--9.7%                                                           584 (21.2%)     2,589 (26.8%)   156 (29.1%)   
  9.7%--15.5%                                                        567 (20.6%)     2,441 (25.3%)   132 (24.6%)   
  15.5%--25.2%                                                       652 (23.7%)     2,233 (23.1%)   100 (18.7%)   
  25.2%--100%                                                        823 (29.9%)     1,992 (20.6%)   122 (22.8%)   
  Missing                                                            123 (4.5%)      403 (4.2%)      26 (4.9%)     

N=12,943

P-values by ANOVA for continuous variables, chi^2^ test for binary/categorical variables

###### 

Physician Characteristics by Physician Practice Type

                                                               Solo                                               Group           Missing                                           
  ------------------------------------------------------------ -------------------------------------------------- --------------- ------------------------------------------------- -----------
  **Mean Primary GnRH agonist Use 2000--2007 (SD)**            0.3 (0.3)                                          0.2 (0.3)       0.1 (0.2)                                         *\<0.001*
  **Time in Practice**                                         385 (29.5%)                                        879 (67.4%)     41 (3.1%)                                         *\<0.001*
  **Male**[\*](#TFN5){ref-type="table-fn"}                     1--5[\*](#TFN5){ref-type="table-fn"} (5--10%)      41 (83.7%)      5--10[\*](#TFN5){ref-type="table-fn"} (10--15%)   *\<0.001*
  **Board Certified**                                          407 (20.4%)                                        1,471 (73.8%)   115 (5.8%)                                        *\<0.001*
  **US Trained**                                               330 (18.4%)                                        1,349 (75.0%)   119 (6.6%)                                        *\<0.001*
  **Medical School Affiliation**                                                                                                                                                    *\<0.001*
  None                                                         258 (27.2%)                                        639 (67.4%)     51 (5.4%)                                         
  Some                                                         192(16.6%)                                         886 (76.7%)     77 (6.7%)                                         
  Missing[\*](#TFN5){ref-type="table-fn"}                      10--15[\*](#TFN5){ref-type="table-fn"} (30--35%)   20 (57.1%)      1--5[\*](#TFN5){ref-type="table-fn"} (5--10%)     
  **Physician Prostate Panel Size (prostate patients/year)**                                                      *\<0.001*                                                         
  0--20                                                        302 (26.2%)                                        768 (66.6%)     83 (7.2%)                                         
  21--37                                                       119 (18.3%)                                        498 (76.5%)     34 (5.2%)                                         
  ≥38                                                          41 (12.3%)                                         279 (83.5%)     14 (4.2%)                                         
  **Proportion Patients Minority**                                                                                                                                                  *\<0.001*
  0%--6.1%                                                     146 (18.8%)                                        582 (75.1%)     47 (6.1%)                                         
  6.2%--19.5%                                                  110 (18.4%)                                        457 (76.6%)     30 (5.0%)                                         
  ≥20.0%                                                       206 (26.9%)                                        506 (66.1%)     54 (7.1%)                                         

N=2,138

P-values by t-test for continuous variables, chi^2^ test for binary/categorical variables; time invariant physician measures described at first entry into cohort

Exact count masked to protect subject confidentiality, per Data Use Agreement

###### 

Multilevel Logistic Regression Model of Time in Practice and Practice Type on GnRH Agonist Overuse

                                                                                                               OR     95% CI
  ------------------------------------------------------------------------------------------------------------ ------ -------------
  **Time in Practice**                                                                                         0.89   0.75, 1.05
  **Solo Practitioner (compared to group practice)**[\*](#TFN7){ref-type="table-fn"}                                  
  Yes                                                                                                          1.65   1.34, 2.02
  Missing                                                                                                      0.82   0.55, 1.23
  **Physician Gender**                                                                                         0.92   0.45, 1.89
  **Board Certification**                                                                                      1.00   0.71, 1.41
  **US Training**                                                                                              0.78   0.62, 0.99
  **Medical School Affiliation (compared to none)**[\*](#TFN7){ref-type="table-fn"}                                   
  Some                                                                                                         0.65   0.55, 0.77
  Missing                                                                                                      0.82   0.39, 1.73
  **Prostate Patient Panel Size (compared to 0--20 patients/year)**                                                   
  21--37                                                                                                       1.04   0.89, 1.21
  ≥38                                                                                                          1.00   0.83, 1.22
  **Proportion Patients Minority (compared to 0%--6.1% minority)**[\*](#TFN7){ref-type="table-fn"}                    
  6.2%--19.5%                                                                                                  0.79   0.66, 0.93
  ≥20.0%                                                                                                       0.81   0.66, 1.00
  **MMA ImplementationPeriod (compared to Pre-MMA)**[\*](#TFN7){ref-type="table-fn"}                                  
  MMA Period                                                                                                   0.78   0.68, 0.91
  Post-MMA                                                                                                     0.54   0.46, 0.64
  **T Stage**                                                                                                  1.36   1.19, 1.57
  **Grade (compared to Well-differentiated)**                                                                         
  Moderately-differentiated 5--7[\*](#TFN7){ref-type="table-fn"}                                               3.12   2.33, 4.17
  Missing                                                                                                      4.90   3.15, 7.60
  **Comorbidities (Compared to None)**                                                                                
  1                                                                                                            1.29   1.13, 1.48
  2                                                                                                            1.25   1.01, 1.55
  ≥3                                                                                                           1.46   1.14, 1.87
  **Patient Age (continuous)**                                                                                 2.30   1.88, 2.82
  **Patient Age squared**                                                                                      1.00   0.99, 1.00
  **Race/ethnicity (compared to Non-Hispanic White)**[\*](#TFN7){ref-type="table-fn"}                                 
  Non-Hispanic Black                                                                                           1.76   1.37, 2.27
  Hispanic                                                                                                     1.41   1.12, 1.79
  Other                                                                                                        1.44   1.04, 1.99
  Missing                                                                                                      1.84   1.40, 2.41
  **Marital Status (compared to Unmarried)**                                                                          
  Married                                                                                                      0.91   0.79, 1.05
  Missing                                                                                                      1.64   1.34, 1.99
  **Pre-treatment Primary Care Use (compared to 0--2 visits in prior year)**[\*](#TFN7){ref-type="table-fn"}          
  3--5                                                                                                         1.64   1.38, 1.96
  ≥6                                                                                                           1.73   1.44, 2.10
  **Primary Care Consultation**                                                                                0.42   0.37, 0.48
  **Radiation Oncology Consultation**                                                                          1.73   1.47, 2.05
  **Medical Oncology Consultation**                                                                            1.03   0.76, 1.40
  **Urology Consultation**                                                                                     6.03   2.93, 12.41
  **Rural Residence**                                                                                          0.94   0.62, 1.44
  **Region (compared to Seattle)**                                                                                    
  Connecticut                                                                                                  4.45   2.56, 7.74
  Detroit                                                                                                      2.39   1.36, 4.19
  Hawaii                                                                                                       4.78   2.02, 11.30
  Iowa                                                                                                         3.38   1.90, 6.01
  New Mexico                                                                                                   2.63   1.37, 5.04
  California                                                                                                   2.54   1.56, 4.15
  Utah                                                                                                         1.46   0.76, 2.83
  Georgia                                                                                                      2.44   1.27, 4.70
  Kentucky                                                                                                     3.17   1.85, 5.44
  New Jersey                                                                                                   5.49   3.32, 9.08
  **Median Income of Patients\' Communities (compared to \<\$35,031)**                                                
  \$35,051--\$46,079                                                                                           0.83   0.69, 1.00
  \$46,084--\$60,668                                                                                           0.83   0.66, 1.05
  \$60,669--\$200,008                                                                                          0.66   0.50, 0.88
  Missing                                                                                                      6.60   0.72, 60.11
  **Proportion of Patient\'s Community w/o High-school Education (compared to \<9.7%)**                               
  9.7%--15.5%                                                                                                  1.18   0.98, 1.43
  15.5%--25.2%                                                                                                 1.24   0.99, 1.55
  25.2%--100%                                                                                                  1.17   0.89, 1.54
  Missing                                                                                                      0.11   0.01, 0.99
  **Constant**                                                                                                 0.00   0.00, 0.00

N=12,943 patients; 2,138 urologists

Constructs tested for joint significance by likelihood ratio test of nested models: Solo practitioner--- X^2^=574.55, p\<0.001Medical school affiliation---X^2^=24.36, p\<0.001Proportion patients minority--- X^2^=7.90, p=0.019MMA implementation period --- X^2^=59.46, p\<0.001Race/ethnicity--- X^2^=39.33, p\<0.001
